Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial Spotlight
Multiple solid tumors
Phase 1/2 CS2009 PD-1/VEGFA/CTLA-4 trispecific antibody in advanced solid tumors
This first-in-human, open-label, multicenter Phase 1/2 study evaluates CS2009, CStone Pharmaceuticals’ trispecific monoclonal antibody designed to block PD-1 (reinvigorates exhausted T cells), CTLA-4 (promotes T-cell…
NCT06741644 First-in-human - Trial result
Head and neck cancer
Multikine (Leukocyte Interleukin Injection) + CIZ neoadjuvant immune conditioning cuts death risk in PD-L1–low, node-negative LA OSCC
Leukocyte Interleukin Injection (LI; “Multikine”) is a locally delivered cytokine-based immunotherapy given pre-operatively and paired with CIZ (low-dose IV cyclophosphamide + indomethacin + zinc/multivitamins) to…
NCT01265849 - Trial result
Small cell lung cancer
LIPI strongly stratifies survival in ES-SCLC but does not predict chemo-IO benefit
In a post hoc pooled analysis of the Phase 3 CASPIAN (durvalumab + platinum/etoposide) and IMpower133 (atezolizumab + carboplatin/etoposide) trials, the Lung Immune Prognostic Index (LIPI; good = dNLR<3 & LDH<ULN;…
- Trial result
Pancreatic cancer
Maximal ablative RT (67.5Gy/15fx or 75Gy/25fx) + capecitabine enables 27% resection and 38% 2-year OS in vascular-encased LAPC
Hypofractionated ablative radiation therapy (A-RT)—dose-escalated external-beam RT (67.5Gy in 15 fractions or 75Gy in 25 fractions) with concurrent capecitabine—was tested in a single-arm Phase 2 MSK trial…
NCT03523312 - Trial result
Brain and CNS tumors
Precision-guided SHH blockade (vismodegib) + HDAC inhibition (vorinostat) accompanies 9-year remission in relapsed SHH medulloblastoma
Vorinostat is an oral histone deacetylase (HDAC) inhibitor and vismodegib is an oral SMO inhibitor targeting the Sonic Hedgehog (SHH) pathway; together with curcumin (multi-target natural product with reported…
NCT02162732 - Trial result Spotlight
Multiple myeloma
Teclistamab (BCMA×CD3 bispecific) drives 76.9% ORR and 25.1-mo mPFS in TCE-RRMM (China)
Teclistamab is a subcutaneous BCMA×CD3 T-cell–redirecting bispecific antibody evaluated in the MajesTEC-1 China cohort with 27.2 months’ follow-up in triple-class exposed RRMM (n=26), dosed 1.5mg/kg weekly with an…
NCT03145181 - Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3 bispecific) maintains ~63–74% ORR in frail RRMM patients in LINKER-MM1
Linvoseltamab is a human BCMA×CD3 T-cell–engaging bispecific antibody evaluated at the 200mg dose in the Phase 1/2, single-arm LINKER-MM1 study (NCT03761108) in heavily pretreated relapsed/refractory multiple…
NCT03761108 - Trial result
Multiple myeloma
Indefinite lenalidomide (IMiD) maintenance fails to improve OS vs 2-year fixed-duration in standard-risk, non-transplant NDMM
Lenalidomide is an oral immunomodulatory drug (IMiD) commonly used as maintenance “until progression” after frontline proteasome inhibitor–lenalidomide induction in transplant-ineligible NDMM; ENDURANCE (Phase 3;…
NCT01863550 - Trial result
Chronic myeloid leukemia
Asciminib (BCR::ABL1 STAMP inhibitor) delivers durable molecular responses in T315I-mutant CML
Asciminib, an allosteric inhibitor that targets the ABL1 myristoyl pocket rather than the ATP-binding site, was evaluated at 200 mg twice daily in a nonrandomized Phase 1 trial (NCT02081378) of heavily pretreated…
NCT02081378 - Trial result
Acute myeloid leukemia and MDS
Venetoclax (BCL-2 inhibitor) + azacitidine: 28-day induction trends to higher CR vs 14-day in OPTI-AML ND-AML
Venetoclax (Ven; oral BCL-2 inhibitor) plus azacitidine (Aza; hypomethylating agent) was tested in OPTI-AML (NCT03013998), a prospective randomized Phase 2 trial in genomically agnostic newly diagnosed AML patients…
NCT03013998 - Trial result
Acute myeloid leukemia and MDS
CPX-351 (liposomal daunorubicin/cytarabine) vs CLAG-M (high-dose cytarabine backbone) in unfit AML: higher CR/CRi with CLAG-M, no OS win overall
CPX-351 is a fixed-ratio liposomal formulation of daunorubicin + cytarabine, while CLAG-M combines cladribine + high-dose cytarabine + G-CSF + mitoxantrone (intensive cytarabine-based chemotherapy). In this…
NCT04195945 - Trial result
Lymphoma
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) delivers 95% ORR and 40.2-mo mPFS in 1L non-blastoid MCL
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax is an oral BCL-2 inhibitor; in the Phase 3 SYMPATICO open-label first-line cohort (NCT03112174), patients with previously untreated…
NCT03112174 - Trial result Spotlight
Lymphoma
Liso-cel (CD19 CAR-T) sustains 68% 3-year PFS in 3L+ follicular lymphoma
Lisocabtagene maraleucel (liso-cel) is an autologous anti-CD19 CAR-T cell therapy evaluated in the Phase 2 TRANSCEND FL study in relapsed/refractory follicular lymphoma after ≥2 prior systemic regimens including…
NCT04245839 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) exposure–response supports 48mg QW→Q2W→Q4W with lower CRS via 3-step ramp
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody; these updated population PK and exposure–response analyses across R/R follicular lymphoma (EPCORE NHL-1: ORR 82.0%, CR 62.5% [N=128]; EPCORE…
NCT03625037 - Trial result
Non-small cell lung cancer
Taletrectinib (next-gen ROS1 TKI) linked to better PFS/OS than crizotinib/entrectinib in ROS1+ NSCLC (MAIC)
Taletrectinib is a next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) evaluated here via an unanchored matching-adjusted indirect comparison (MAIC) using pooled, single-arm TRUST-I (NCT04395677) and…
NCT04395677 - Trial result
Non-small cell lung cancer
Ociperlimab (anti‑TIGIT) + Tislelizumab (anti‑PD‑1) fails to beat pembrolizumab OS in PD‑L1≥50% 1L NSCLC
Ociperlimab is an anti‑TIGIT antibody combined with the anti‑PD‑1 tislelizumab to deepen checkpoint blockade; AdvanTIG‑302 (Phase 3; NCT04746924) randomized untreated stage III/IV (locally advanced unresectable or…
NCT04746924 - Trial result
Non-small cell lung cancer
PEF (irreversible electroporation) ablation + perioperative chemo‑IO delivers 75% pCR in resectable NSCLC (case series)
The VIGOR study (NCT05583188) evaluated adding neoadjuvant pulsed electric field (PEF) ablation (a non-thermal electroporation-based local tumor ablation) before standard-of-care neoadjuvant immune checkpoint…
NCT05583188 - Trial result
Non-small cell lung cancer
TRIDENT ML signature flags KRAS/STK11-mutant, EGFR/FGFR3/CDKN2A–WT non-squamous NSCLC for bigger tremelimumab add-on OS benefit
TRIDENT is a post hoc machine-learning analysis of the Phase 3 POSEIDON trial (NCT03164616; data cut-off March 12, 2021) evaluating whether adding tremelimumab (anti–CTLA-4) to durvalumab (anti–PD-L1) plus…
NCT03164616 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19×CD3 BiTE) consolidation cuts relapse in high-risk Ph− adult B‑ALL (5‑yr CIR 23% vs 49%)
Blinatumomab is a CD19×CD3 bispecific T‑cell engager given here as an immunotherapy “overlay” on intensive chemotherapy, tested in the Phase 2 GRAALL‑2014/B‑QUEST substudy in newly diagnosed high-risk (KMT2A‑r, IKZF1…
NCT03709719 - Trial result Spotlight
Breast cancer
Camizestrant (oral SERD) + CDK4/6i doubles PFS when ctDNA ESR1 mutations emerge on 1L AI
Camizestrant (AZD9833) is an oral selective estrogen receptor degrader (SERD) designed to antagonize and degrade ER, including mutant ER, and in SERENA-6 (Phase 3, double-blind) it was used as an early “molecular…
NCT04964934 - Trial result
Breast cancer
PH FDC SC (pertuzumab+trastuzumab) dual-HER2 blockade matches IV outcomes at 4 years in early breast cancer
PH FDC SC is a fixed-dose, subcutaneous co-formulation of pertuzumab (HER2 dimerization inhibitor) and trastuzumab (anti-HER2 mAb) designed to replace IV dosing while preserving exposure; in the Phase III FeDeriCa…
NCT03493854 - Trial result
Breast cancer
Pembrolizumab (PD-1) KEYNOTE-522 neoadjuvant regimen: gBRCA+ trends to higher pCR and 2-year RFS in early TNBC
Pembrolizumab, an anti–PD-1 antibody, combined with platinum/taxane → anthracycline/cyclophosphamide chemotherapy per the KEYNOTE-522 regimen (NCT03036488) was evaluated in a retrospective single-center real-world…
NCT03036488 - Trial result
Breast cancer
PLD (pegylated liposomal doxorubicin; immunogenic anthracycline) + pembrolizumab (PD-1) posts 67% disease control and 10 responses in heavily pretreated ER+/HER2− mBC
Pegylated liposomal doxorubicin (PLD), a liposomal anthracycline that can induce immunogenic cell death, was combined with pembrolizumab (PEM), an anti–PD-1 checkpoint inhibitor, in a Phase Ib, 2-cohort dose/schedule…
- Trial result Spotlight
Lymphoma
Nivolumab (PD-1) + AVD lifts 3-year PFS in EBV+ and non–nodular sclerosis advanced cHL vs BV-AVD
Nivolumab-AVD (N-AVD) combines PD-1 blockade (nivolumab) with doxorubicin/vinblastine/dacarbazine chemotherapy, and in the Phase 3 SWOG S1826 frontline trial in stage III–IV classic Hodgkin lymphoma (NCT03907488),…
NCT03907488 - Trial result Spotlight
Kidney cancer
Panitumumab-based EGFR blockade drives 53.9% ORR in platinum-refractory renal medullary carcinoma
SMARCB1-deficient renal medullary carcinoma (RMC)—a rare, hypoxic medullary kidney cancer enriched in young patients of African descent with sickle cell trait—was historically treated with platinum-based chemotherapy…
NCT06444880 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + Radium-223 (bone-seeking α-emitter) fails to extend SSE-free survival in mRCC bone mets (RADICAL)
Radium-223 dichloride is an osteotropic alpha-particle radiopharmaceutical, combined here with cabozantinib, an oral multikinase TKI (VEGFR2/MET/AXL) with known activity in RCC bone disease; RADICAL (Alliance…
NCT04071223 - Trial result
Prostate cancer
RTIRE (IRE focal ablation + reduced-dose RT) yields 100% negative 12‑mo biopsy in intermediate‑risk prostate cancer
RTIRE combines irreversible electroporation (IRE), a nonthermal focal ablation approach, followed by reduced-dose external-beam radiation (32.5Gy in 5 fractions) to treat MRI-visible grade group 2–3 index lesions in…
NCT05345444 - Trial result
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR antagonist) shows “early rPFS, late OS” signal in HRR–non-deficient/unknown mCRPC (post hoc)
Talazoparib is an oral PARP inhibitor combined with enzalutamide, an androgen-receptor signaling inhibitor, in first-line metastatic castration-resistant prostate cancer (mCRPC); this post hoc analysis of TALAPRO-2…
NCT03395197 - Trial result
Lymphoma
Pola (anti-CD79b ADC) + R-CHP Delivers 93% ORR/83% CR in Real-World Frontline DLBCL (Japan)
POLASTAR (jRCT1071220082) is a prospective, multicenter Japanese real-world study of polatuzumab vedotin (anti-CD79b antibody–drug conjugate delivering MMAE) plus rituximab, cyclophosphamide, doxorubicin, and…
- Trial result
Lymphoma
Englumafusp alfa (CD19–4-1BBL costimulator) + glofitamab (CD20×CD3) drives 56.6% CMR in R/R aggressive B‑NHL
Englumafusp alfa is an off-the-shelf CD19-targeting 4-1BBL co-stimulatory fusion protein designed to augment T-cell activation, combined here with glofitamab, a CD20×CD3 T-cell–engaging bispecific antibody, with…
NCT04077723
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.